

Nivolumab CheckMate 649

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

OS



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Nivolumab CheckMate 649

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Treatment for adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and oesophageal adenocarcinoma

Experimental Arm: Nivolumab + Fluoropyrimidine + platinum ChT (FOLFOX or CAPOX)

Control Arm: ChT (FOLFOX or CAPOX)



